{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:20:55Z","timestamp":1776370855482,"version":"3.51.2"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Diagnosis of acute myeloid leukemia (AML) is associated with poor outcome in elderly and unfit patients. Recently, approval of the\n                      <jats:italic>BCL-2<\/jats:italic>\n                      inhibitor venetoclax (VEN) in combination with hypo-methylating agents (HMA) led to a significant improvement of response rates and survival. Further, application in the relapsed or refractory (r\/r) AML setting or in context of allogeneic stem cell transplantation (alloHSCT) seems feasible.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and patients<\/jats:title>\n                    <jats:p>Fifty-six consecutive adult AML patients on VEN from January 2019 to June 2021 were analyzed retrospectively. Patients received VEN either as first-line treatment, as subsequent therapy (r\/r AML excluding prior alloHSCT), or at relapse after alloHSCT. VEN was administered orally in 28-day cycles either combined with HMA or low-dose cytarabine (LDAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After a median follow-up of 11.5 (range 6.1\u201322.3) months, median overall survival (OS) from start of VEN treatment was 13.3 (2.2\u201320.5) months, 5.0 (0.8\u201324.3) months and 4.0 (1.5\u201322.1) months for first-line, subsequent line treatment and at relapse post-alloHSCT, respectively. Median OS was 11.5 (10\u201322.3) months from start of VEN when subsequent alloHSCT was carried out. Relapse-free survival (RFS) for the total cohort was 10.2 (2.2 \u2013 24.3) months. Overall response rate (composite complete remission\u2009+\u2009partial remission) was 51.8% for the total cohort (61.1% for VEN first-line treatment, 52.2% for subsequent line and 42.8% at relapse post-alloHSCT). Subgroup analysis revealed a significantly reduced median OS in\n                      <jats:italic>FLT3-ITD<\/jats:italic>\n                      mutated AML with 3.4 (1.9\u20134.9) months versus 10.4 (0.8\u201324.3) months for non-mutated cases, (HR 4.45, 95% CI 0.89\u201322.13,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002). Patients harboring\n                      <jats:italic>NPM1<\/jats:italic>\n                      or\n                      <jats:italic>IDH1\/2<\/jats:italic>\n                      mutations lacking co-occurrence of\n                      <jats:italic>FLT3-ITD<\/jats:italic>\n                      showed a survival advantage over patients without those mutations (11.2 (5\u201324.3) months versus 5.0 (0.8\u201322.1) months, respectively, (HR 0.53, 95% CI 0.23 \u2013 1.21,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.131). Multivariate analysis revealed mutated NPM1 as a significant prognostic variable for achieving complete remission (CR) (HR 19.14, 95% CI 2.30 \u2013 436.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The most common adverse events were hematological, with grade 3 and 4 neutropenia and thrombocytopenia reported in 44.6% and 14.5% of patients, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Detailed analyses on efficacy for common clinical scenarios, such as first-line treatment, subsequent therapy (r\/r AML), and application prior to and post-alloHSCT, are presented. The findings suggest VEN treatment combinations efficacious not only in first-line setting but also in r\/r AML. Furthermore, VEN might play a role in a subgroup of patients with failure to conventional chemotherapy as a salvage regimen aiming for potential curative alloHSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-022-03930-5","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T01:02:27Z","timestamp":1643590947000},"page":"3191-3202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia"],"prefix":"10.1007","volume":"148","author":[{"given":"Maximilian","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen J.","family":"Frietsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Schrenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Hammersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Prims","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-8988","authenticated-orcid":false,"given":"Ulf","family":"Schnetzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"3930_CR1","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A et al (2018) Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica 103:e404\u2013e407","journal-title":"Haematologica"},{"key":"3930_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.26190","volume":"96","author":"A Apel","year":"2021","unstructured":"Apel A, Moshe Y, Ofran Y et al (2021) Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. Am J Hematol 96:790\u2013795","journal-title":"Am J Hematol"},{"key":"3930_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1586\/ehm.10.32","volume":"3","author":"AJ Barrett","year":"2010","unstructured":"Barrett AJ, Battiwalla M (2010) Relapse after allogeneic stem cell transplantation. Expert Rev Hematol 3:429\u2013441","journal-title":"Expert Rev Hematol"},{"key":"3930_CR4","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW, Trenschel R, Stelljes M et al (2020) Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol 7:e28\u2013e39","journal-title":"Lancet Haematol"},{"key":"3930_CR5","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/bmt.2011.242","volume":"47","author":"J Casper","year":"2012","unstructured":"Casper J, Holowiecki J, Trenschel R et al (2012) Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning. Bone Marrow Transplant 47:1171\u20131177","journal-title":"Bone Marrow Transplant"},{"key":"3930_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93:401\u2013407","journal-title":"Am J Hematol"},{"key":"3930_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"3930_CR8","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K et al (2021) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 39:2768\u20132778","journal-title":"J Clin Oncol"},{"key":"3930_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"3930_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126:291\u2013299","journal-title":"Blood"},{"key":"3930_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.leukres.2010.07.015","volume":"35","author":"RP Gale","year":"2011","unstructured":"Gale RP, Barosi G, Barbui T et al (2011) What are RBC-transfusion-dependence and -independence? Leuk Res 35:8\u201311","journal-title":"Leuk Res"},{"key":"3930_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/bmt.2017.83","volume":"52","author":"YS Jethava","year":"2017","unstructured":"Jethava YS, Sica S, Savani B et al (2017) Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone Marrow Transplant 52:1504\u20131511","journal-title":"Bone Marrow Transplant"},{"key":"3930_CR13","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA (2019) How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33:2795\u20132804","journal-title":"Leukemia"},{"key":"3930_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41408-021-00437-z","volume":"11","author":"M Joshi","year":"2021","unstructured":"Joshi M, Cook J, McCullough K et al (2021) Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer J 11:49","journal-title":"Blood Cancer J"},{"key":"3930_CR15","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A et al (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood 113:4179\u20134187","journal-title":"Blood"},{"key":"3930_CR16","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670\u20132677","journal-title":"J Clin Oncol"},{"key":"3930_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17746","author":"S Kayser","year":"2021","unstructured":"Kayser S, Levis MJ (2021) Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.17746","journal-title":"Br J Haematol"},{"key":"3930_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01362-8","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Qiao W et al (2021) Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: a propensity score-matched analysis. Cancer. https:\/\/doi.org\/10.1016\/S2152-2650(21)01362-8","journal-title":"Cancer"},{"key":"3930_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","volume":"11","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Daver NG et al (2021) Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11:25","journal-title":"Blood Cancer J"},{"key":"3930_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/2040620711402533","volume":"2","author":"JK Mangan","year":"2011","unstructured":"Mangan JK, Luger SM (2011) Salvage therapy for relapsed or refractory acute myeloid leukemia. Ther Adv Hematol 2:73\u201382","journal-title":"Ther Adv Hematol"},{"key":"3930_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000516655","volume":"161","author":"J McGowan-Jordan","year":"2021","unstructured":"McGowan-Jordan J, Hastings R, Moore S (2021) Re: International system for human cytogenetic or cytogenomic nomenclature (ISCN): some thoughts, by T. Liehr. Cytogenet Genome Res 161:225\u2013226","journal-title":"Cytogenet Genome Res"},{"key":"3930_CR22","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.bbmt.2016.03.023","volume":"22","author":"IH Motabi","year":"2016","unstructured":"Motabi IH, Ghobadi A, Liu J et al (2016) Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant. Biol Blood Marrow Transplant 22:1324\u20131329","journal-title":"Biol Blood Marrow Transplant"},{"key":"3930_CR23","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 381:1728\u20131740","journal-title":"N Engl J Med"},{"key":"3930_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081684","author":"M Piccini","year":"2021","unstructured":"Piccini M, Pilerci S, Merlini M et al (2021) Venetoclax-based regimens for relapsed\/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10081684","journal-title":"J Clin Med"},{"key":"3930_CR25","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","volume":"3","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Amaya M, Strati P, Konopleva MY (2019) Venetoclax for AML: changing the treatment paradigm. Blood Adv 3:4326\u20134335","journal-title":"Blood Adv"},{"key":"3930_CR26","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/cncr.33508","volume":"127","author":"CR Rausch","year":"2021","unstructured":"Rausch CR, DiNardo CD, Maiti A et al (2021) Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127:2489\u20132499","journal-title":"Cancer"},{"key":"3930_CR27","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Cortes J, Faderl S et al (2010) Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 116:5818\u20135823 (quiz 6153)","journal-title":"Blood"},{"key":"3930_CR28","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz GJ, Rosenblat T, Arellano M et al (2014) International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia. J Clin Oncol 32:1919\u20131926","journal-title":"J Clin Oncol"},{"key":"3930_CR29","doi-asserted-by":"publisher","first-page":"562558","DOI":"10.3389\/fonc.2020.562558","volume":"10","author":"B Samra","year":"2020","unstructured":"Samra B, Konopleva M, Isidori A et al (2020) Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions. Front Oncol 10:562558","journal-title":"Front Oncol"},{"key":"3930_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3324\/haematol.2017.168716","volume":"103","author":"C Schmid","year":"2018","unstructured":"Schmid C, de Wreede LC, van Biezen A et al (2018) Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the chronic malignancies working party of the European society of blood and marrow transplantation. Haematologica 103:237\u2013245","journal-title":"Haematologica"},{"key":"3930_CR31","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA et al (2021) Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica 106:1034\u20131046","journal-title":"Haematologica"},{"key":"3930_CR32","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","volume":"2","author":"M Stahl","year":"2018","unstructured":"Stahl M, DeVeaux M, Montesinos P et al (2018) Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv 2:923\u2013932","journal-title":"Blood Adv"},{"key":"3930_CR33","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.3324\/haematol.2019.222323","volume":"105","author":"S Stasik","year":"2020","unstructured":"Stasik S, Middeke JM, Kramer M et al (2020) EZH2 mutations and impact on clinical outcome: an analysis in 1604 patients with newly diagnosed acute myeloid leukemia. Haematologica 105:e228\u2013e231","journal-title":"Haematologica"},{"key":"3930_CR34","doi-asserted-by":"publisher","first-page":"649209","DOI":"10.3389\/fonc.2021.649209","volume":"11","author":"ME Tenold","year":"2021","unstructured":"Tenold ME, Moskoff BN, Benjamin DJ et al (2021) Outcomes of adults with relapsed\/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center. Front Oncol 11:649209","journal-title":"Front Oncol"},{"key":"3930_CR35","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135:2137\u20132145","journal-title":"Blood"},{"key":"3930_CR36","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E et al (2019) Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv 3:2911\u20132919","journal-title":"Blood Adv"},{"key":"3930_CR37","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, K\u00f6hnke T et al (2020) Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer 1:826\u2013839","journal-title":"Nat Cancer"},{"key":"3930_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","volume":"6","author":"R Zhu","year":"2021","unstructured":"Zhu R, Li L, Nguyen B et al (2021) FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther 6:186","journal-title":"Signal Transduct Target Ther"},{"key":"3930_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01416-5","author":"A Zucenka","year":"2021","unstructured":"Zucenka A, Vaitekenaite V, Maneikis K et al (2021) Venetoclax-based salvage therapy followed by venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/s41409-021-01416-5","journal-title":"Bone Marrow Transplant"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03930-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-03930-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03930-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T07:38:03Z","timestamp":1663918683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-03930-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3930"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-03930-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1026952\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data analysis has been approved by local ethics committee (3967\u201312\/13 for SAL registry).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent of patients for participation was obtained when registered for SAL registry (see above).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent of patients to publish was obtained when registered for SAL registry (see above).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}